From: Screening for cervical cancer: a systematic review and meta-analysis
Outcome | Illustrative comparative risksa | Â | Â | Â | |
---|---|---|---|---|---|
Assumed risk for no screening Number per million | Corresponding risk for screening Number per million (95% CI) | Relative effect (95% CI) | Number of participants (Number of studies) | GRADE quality of evidenceb | |
Cervical cancer mortality (invited to HPV test or cytology versus no screening) RCT; follow-up: 8 years | 2,033c | 1,330 (964, 1,834)c | RR 0.65 (0.47, 0.90)d | 97,672 (1e) | Moderatef,g,h,i,j |
Incidence of stage II+ cervical cancer (invited to HPV test or cytology versus no screening) RCT; follow-up: 8 years | 2,604c | 1,466 (1,093, 1,966)c | rr 0.56 (0.42, 0.75)d | 97,672 (1e) | Moderatef,g,h,i,j |
Incidence of invasive cervical cancer (invited to HVP test or cytology versus no screening) RCT; follow-up: 8 years | 3,747c | 4,216 (3,401, 5,226)c | rr 1.12 (0.91, 1.39)d | 97,672 (1e) | Moderatef,g,h,i,j |
Incidence of invasive cervical cancer (cytology versus no screening) cohort study; follow-up: 3 years | 1,596k | 609 (368, 1,006)l | rr 0.38 (0.23, 0.63) | 116,022 (1m) | Low g,i,j,n |
Exposure to cytology screening (cases: diagnosed with invasive cervical cancer; controls: no cervical cancer); exposure: in previous 3 years to lifetime | 4,781 cases and 17,916 controls | OR 0.35 (0.30, 0.41) | 22,697 (13o) | Very low p,q,r,s |